Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Jazz Pharmaceuticals plc’s stock clocked out at $172.12, down -2.50% from its previous closing price of $176.53. In other words, the price has decreased by -$2.50 from its previous closing price. On the day, 1.52 million shares were traded. JAZZ stock price reached its highest trading level at $175.48 during the session, while it also had its lowest trading level at $170.57.
Ratios:
To gain a deeper understanding of JAZZ’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.11 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 7.83. For the most recent quarter (mrq), Quick Ratio is recorded 1.44 and its Current Ratio is at 1.65. In the meantime, Its Debt-to-Equity ratio is 1.37 whereas as Long-Term Debt/Eq ratio is at 1.11.
On July 15, 2025, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $152. UBS Upgraded its Neutral to Buy on March 07, 2025, whereas the target price for the stock was revised from $145 to $179.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 02 ’25 when O’Keefe Kenneth W bought 1,249 shares for $176.59 per share.
COZADD BRUCE C sold 77,500 shares of JAZZ for $13,780,337 on Nov 26 ’25. The Director now owns 393,332 shares after completing the transaction at $177.81 per share. On Nov 26 ’25, another insider, BRUCE COZADD, who serves as the Director of the company, bought 77,500 shares for $177.81 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JAZZ now has a Market Capitalization of 10458891264 and an Enterprise Value of 13841781760. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.52 while its Price-to-Book (P/B) ratio in mrq is 2.64. Its current Enterprise Value per Revenue stands at 3.329 whereas that against EBITDA is 8.608.
Stock Price History:
The Beta on a monthly basis for JAZZ is 0.31, which has changed by 0.41499507 over the last 52 weeks, in comparison to a change of 0.12607694 over the same period for the S&P500. Over the past 52 weeks, JAZZ has reached a high of $182.99, while it has fallen to a 52-week low of $95.49. The 50-Day Moving Average of the stock is 19.72%, while the 200-Day Moving Average is calculated to be 38.03%.
Shares Statistics:
It appears that JAZZ traded 945.20K shares on average per day over the past three months and 2195380 shares per day over the past ten days. A total of 60.74M shares are outstanding, with a floating share count of 57.99M. Insiders hold about 4.57% of the company’s shares, while institutions hold 98.79% stake in the company. Shares short for JAZZ as of 1763078400 were 4839654 with a Short Ratio of 5.12, compared to 1760486400 on 4689812. Therefore, it implies a Short% of Shares Outstanding of 4839654 and a Short% of Float of 9.2.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 16.0 analysts currently analyzing and rating the stock of Jazz Pharmaceuticals plc (JAZZ).The consensus estimate for the next quarter is $4.44, with high estimates of $5.96 and low estimates of $3.52.
Analysts are recommending an EPS of between $8.82 and $7.71 for the fiscal current year, implying an average EPS of $8.11. EPS for the following year is $22.71, with 16.0 analysts recommending between $30.05 and $19.92.
Revenue Estimates
In. The current quarter, 15 analysts expect revenue to total $1.16B. It ranges from a high estimate of $1.22B to a low estimate of $1.11B. As of. The current estimate, Jazz Pharmaceuticals plc’s year-ago sales were $1.09BFor the next quarter, 15 analysts are estimating revenue of $977.05M. There is a high estimate of $1.1B for the next quarter, whereas the lowest estimate is $903.7M.
A total of 17 analysts have provided revenue estimates for JAZZ’s current fiscal year. The highest revenue estimate was $4.29B, while the lowest revenue estimate was $4.18B, resulting in an average revenue estimate of $4.23B. In the same quarter a year ago, actual revenue was $4.07BBased on 17 analysts’ estimates, the company’s revenue will be $4.52B in the next fiscal year. The high estimate is $4.98B and the low estimate is $4.12B.
